| Lenvatinib versus placebo in radioiodine-refractory thyroid cancer M Schlumberger, M Tahara, LJ Wirth, B Robinson, MS Brose, R Elisei, ... New England Journal of Medicine 372 (7), 621-630, 2015 | 2038 | 2015 |
| Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease S Tsui, V Naik, N Hoa, CJ Hwang, NF Afifiyan, A Sinha Hikim, ... The Journal of Immunology 181 (6), 4397-4405, 2008 | 392 | 2008 |
| Increased generation of fibrocytes in thyroid-associated ophthalmopathy RS Douglas, NF Afifiyan, CJ Hwang, K Chong, U Haider, P Richards, ... The Journal of Clinical Endocrinology & Metabolism 95 (1), 430-438, 2010 | 220 | 2010 |
| Cytokines, Graves' disease, and thyroid-associated ophthalmopathy AG Gianoukakis, N Khadavi, TJ Smith Thyroid 18 (9), 953-958, 2008 | 187 | 2008 |
| B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis RS Douglas, V Naik, CJ Hwang, NF Afifiyan, AG Gianoukakis, D Sand, ... The Journal of Immunology 181 (8), 5768-5774, 2008 | 156 | 2008 |
| Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis RS Douglas, AG Gianoukakis, S Kamat, TJ Smith The Journal of Immunology 178 (5), 3281-3287, 2007 | 148 | 2007 |
| Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy TJ Smith, CC Tsai, MJ Shih, S Tsui, B Chen, R Han, V Naik, CS King, ... Thyroid 18 (9), 983-988, 2008 | 122 | 2008 |
| Pancreatic neuroendocrine tumors E Batcher, P Madaj, AG Gianoukakis Endocrine research 36 (1), 35-43, 2011 | 109 | 2011 |
| Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes RI Haddad, M Schlumberger, LJ Wirth, EJ Sherman, MH Shah, ... Endocrine 56, 121-128, 2017 | 96 | 2017 |
| Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer M Tahara, MS Brose, LJ Wirth, T Suzuki, H Miyagishi, K Fujino, CE Dutcus, ... European Journal of Cancer 106, 61-68, 2019 | 84 | 2019 |
| Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates M Karam, A Gianoukakis, PJ Feustel, A Cheema, ES Postal, JA Cooper Nuclear medicine communications 24 (5), 489-495, 2003 | 77 | 2003 |
| A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). M Schlumberger, M Tahara, LJ Wirth, B Robinson, MS Brose, R Elisei, ... Journal of Clinical Oncology 32 (15_suppl), LBA6008-LBA6008, 2014 | 76 | 2014 |
| Prolonged duration of response in lenvatinib responders with thyroid cancer AG Gianoukakis, CE Dutcus, N Batty, M Guo, M Baig Endocrine-related cancer 25 (6), 699-704, 2018 | 74 | 2018 |
| Characterization of the anaemia associated with Graves’ disease AG Gianoukakis, MJ Leigh, P Richards, PD Christenson, A Hakimian, ... Clinical endocrinology 70 (5), 781-787, 2009 | 71 | 2009 |
| Comparison of diabetes care provided by an endocrinology clinic and a primary-care clinic MC Leinung, AG Gianoukakis, DW Lee, SL Jeronis, J Desemone Endocrine Practice 6 (5), 361-366, 2000 | 66 | 2000 |
| Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves’ disease with potent thyroid-stimulating activity but differential blocking activity … JA Gilbert, AG Gianoukakis, S Salehi, J Moorhead, PV Rao, MZ Khan, ... The Journal of Immunology 176 (8), 5084-5092, 2006 | 63 | 2006 |
| Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease TJ Smith, DA Padovani-Claudio, Y Lu, N Raychaudhuri, R Fernando, ... The Journal of Clinical Endocrinology & Metabolism 96 (12), 3827-3837, 2011 | 60 | 2011 |
| A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer MS Brose, Y Panaseykin, B Konda, C de La Fouchardiere, BGM Hughes, ... The Journal of Clinical Endocrinology & Metabolism 107 (3), 776-787, 2022 | 55 | 2022 |
| Immunoglobulin G from patients with Graves’ disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of … AG Gianoukakis, RS Douglas, CS King, WW Cruikshank, TJ Smith Endocrinology 147 (4), 1941-1949, 2006 | 52 | 2006 |
| Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy AG Gianoukakis, TJ Smith Current Opinion in Endocrinology, Diabetes and Obesity 15 (5), 446-452, 2008 | 51 | 2008 |
